A clinical trial of a new drug derived from marijuana to treat seizures in children has received approval, and patients are receiving the medication, according to the physician directing it.
Following a rigorous review process, the trial is being conducted by the University of Mississippi Medical Center and the UM School of Pharmacy on UMMC’s Jackson campus.
The study’s focus is to determine the safety and tolerability of the medication for children with severe epilepsy whose seizures are uncontrolled by other means, said principal investigator Dr. Brad Ingram, UMMC associate professor of pediatric neurology and director of the Pediatric Comprehensive Epilepsy Program.
Ingram described the six-month trial, which involves 10 patients, as “compassionate care” for “the sickest of the sick.”
“These are patients whose lives have been devastated by their epilepsy, even up to their abilities to walk, talk, or participate in simple activities of self care,” Ingram said.
Required approvals were obtained from the